{
    "name": "brinzolamide/brimonidine",
    "comment": "Rx",
    "other_names": [
        "Simbrinza"
    ],
    "classes": [
        "Antiglaucoma",
        "Combos"
    ],
    "source": "https://reference.medscape.com/drug/simbrinza-brinzolamide-brimonidine-999841",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: Unknown whether distributed in human breast milk; do not breast feed"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Unknown whether distributed in human breast milk; do not breast feed"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Neonates and infants (younger than 2 yr)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Contains brinzolamide, a sulfonamide; caution with history of sulfonamide allergy",
                "Carbonic anhydrase activity observed in both the cytoplasm and around the plasma membranes of the corneal endothelium, and therefore there is an increased potential for developing corneal edema in patients with low endothelial cell counts",
                "Brinzolamide and its metabolite are excreted predominantly by the kidney and is not recommended in patients with severe renal impairment",
                "Not studied in patients with acute angle-closure glaucoma",
                "Contains benzalkonium chloride (preservative); remove contact lenses during instillation to avoid absorption by soft lenses (may reinsert 15 minutes after instillation)",
                "Brimonidine elicits <5% mean decrease in blood pressure 2 hr after instillation; caution with severe cardiovascular disease",
                "Not studied with severe hepatic impairment",
                "Brimonidine may potentiate syndromes associated with vascular insufficiency (eg, depression, cerebral or coronary insufficiency, Raynaudâ€™s phenomenon, orthostatic hypotension, thromboangiitis obliterans)",
                "Bacterial keratitis reported from inadvertent contamination of multiple-dose containers of topical ophthalmics"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "isocarboxazid",
            "description": {
                "common": "isocarboxazid, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "linezolid",
            "description": {
                "common": "linezolid, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "phenelzine",
            "description": {
                "common": "phenelzine, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "procarbazine",
            "description": {
                "common": "procarbazine, brimonidine. Mechanism: unknown. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rasagiline",
            "description": {
                "common": "rasagiline, brimonidine. Mechanism: unknown. Contraindicated. Brimonidine should not be used in patients receiving MAO inhibitors."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "selegiline",
            "description": {
                "common": "selegiline, brimonidine. Mechanism: unknown. Contraindicated. Coadministration is contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "selegiline transdermal",
            "description": {
                "common": "selegiline transdermal, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tranylcypromine",
            "description": {
                "common": "tranylcypromine, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acrivastine",
            "description": {
                "common": "acrivastine and brimonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amantadine",
            "description": {
                "common": "brinzolamide will decrease the level or effect of amantadine by  Other (see comment). Modify Therapy/Monitor Closely. Excretion rate of amantadine increases rapidly when urine is acidic, administration of urine acidifying drugs may increase elimination of amantadine from the body. Monitor for efficacy of amantadine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amifostine",
            "description": {
                "common": "amifostine, brimonidine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. When amifostine is used at chemotherapeutic doses, withhold blood pressure lowering medications for 24 hr prior to amifostine; if blood pressure lowering medication cannot be withheld, do not administer amifostine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amisulpride",
            "description": {
                "common": "amisulpride and brimonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine and brimonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine transdermal",
            "description": {
                "common": "asenapine transdermal and brimonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin",
            "description": {
                "common": "brinzolamide, aspirin.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin rectal",
            "description": {
                "common": "brinzolamide, aspirin rectal.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "brinzolamide, aspirin/citric acid/sodium bicarbonate.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "avapritinib and brimonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "balsalazide",
            "description": {
                "common": "brinzolamide, balsalazide.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "benzhydrocodone/acetaminophen and brimonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "brexpiprazole and brimonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "candesartan",
            "description": {
                "common": "brimonidine increases effects of candesartan by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "choline magnesium trisalicylate",
            "description": {
                "common": "brinzolamide, choline magnesium trisalicylate.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diflunisal",
            "description": {
                "common": "brinzolamide, diflunisal.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "brimonidine increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eprosartan",
            "description": {
                "common": "brimonidine increases effects of eprosartan by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esketamine intranasal",
            "description": {
                "common": "esketamine intranasal, brimonidine.\nEither increases toxicity of the other by sedation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "irbesartan",
            "description": {
                "common": "brimonidine increases effects of irbesartan by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lasmiditan",
            "description": {
                "common": "lasmiditan, brimonidine.\nEither increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisdexamfetamine",
            "description": {
                "common": "brinzolamide will increase the level or effect of lisdexamfetamine by  passive renal tubular reabsorption - basic urine. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "losartan",
            "description": {
                "common": "brimonidine increases effects of losartan by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "lurasidone, brimonidine.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Potential for increased CNS depressant effects when used concurrently; monitor for increased sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mesalamine",
            "description": {
                "common": "brinzolamide, mesalamine.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroglycerin rectal",
            "description": {
                "common": "nitroglycerin rectal, brimonidine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olmesartan",
            "description": {
                "common": "brimonidine increases effects of olmesartan by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sacubitril/valsartan",
            "description": {
                "common": "brimonidine increases effects of sacubitril/valsartan by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salicylates (non-asa)",
            "description": {
                "common": "brinzolamide, salicylates (non-asa).\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salsalate",
            "description": {
                "common": "brinzolamide, salsalate.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, brimonidine.\nEither increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfasalazine",
            "description": {
                "common": "brinzolamide, sulfasalazine.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "telmisartan",
            "description": {
                "common": "brimonidine increases effects of telmisartan by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "topiramate",
            "description": {
                "common": "topiramate, brinzolamide.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of kidney stone formation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valsartan",
            "description": {
                "common": "brimonidine increases effects of valsartan by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "willow bark",
            "description": {
                "common": "brinzolamide, willow bark.\nEither increases levels of the other by Other (see comment). Use Caution/Monitor. \nComment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acebutolol",
            "description": {
                "common": "brimonidine increases effects of acebutolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alfentanil",
            "description": {
                "common": "brimonidine increases effects of alfentanil by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alfuzosin",
            "description": {
                "common": "brimonidine increases effects of alfuzosin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alprazolam",
            "description": {
                "common": "brimonidine increases effects of alprazolam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amiloride",
            "description": {
                "common": "brimonidine increases effects of amiloride by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "amitriptyline decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amlodipine",
            "description": {
                "common": "brimonidine increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amobarbital",
            "description": {
                "common": "brimonidine increases effects of amobarbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amoxapine",
            "description": {
                "common": "amoxapine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "butabarbital",
            "description": {
                "common": "brinzolamide, butabarbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "brimonidine increases effects of aripiprazole by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "asenapine",
            "description": {
                "common": "brimonidine increases effects of asenapine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "atenolol",
            "description": {
                "common": "brimonidine increases effects of atenolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "azelastine",
            "description": {
                "common": "brimonidine increases effects of azelastine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "belladonna and opium",
            "description": {
                "common": "brimonidine increases effects of belladonna and opium by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "benazepril",
            "description": {
                "common": "brimonidine increases effects of benazepril by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bendroflumethiazide",
            "description": {
                "common": "brimonidine increases effects of bendroflumethiazide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "benperidol",
            "description": {
                "common": "brimonidine increases effects of benperidol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "betaxolol",
            "description": {
                "common": "brimonidine increases effects of betaxolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bisoprolol",
            "description": {
                "common": "brimonidine increases effects of bisoprolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bosentan",
            "description": {
                "common": "brimonidine increases effects of bosentan by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "brompheniramine",
            "description": {
                "common": "brimonidine increases effects of brompheniramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bumetanide",
            "description": {
                "common": "brimonidine increases effects of bumetanide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "buprenorphine",
            "description": {
                "common": "brimonidine increases effects of buprenorphine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "buprenorphine buccal",
            "description": {
                "common": "brimonidine increases effects of buprenorphine buccal by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "butabarbital",
            "description": {
                "common": "brimonidine increases effects of butabarbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "butalbital",
            "description": {
                "common": "brimonidine increases effects of butalbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "butorphanol",
            "description": {
                "common": "brimonidine increases effects of butorphanol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethotoin",
            "description": {
                "common": "brinzolamide, ethotoin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "captopril",
            "description": {
                "common": "brimonidine increases effects of captopril by pharmacodynamic synergism. Minor/Significance Unknown. Both drugs lower blood pressure. Monitor blood pressure."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carbinoxamine",
            "description": {
                "common": "brimonidine increases effects of carbinoxamine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carvedilol",
            "description": {
                "common": "brimonidine increases effects of carvedilol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "celiprolol",
            "description": {
                "common": "brimonidine increases effects of celiprolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chloral hydrate",
            "description": {
                "common": "brimonidine increases effects of chloral hydrate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlordiazepoxide",
            "description": {
                "common": "brimonidine increases effects of chlordiazepoxide by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "brimonidine increases effects of chlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorpheniramine",
            "description": {
                "common": "brimonidine increases effects of chlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "brimonidine increases effects of chlorpromazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "brimonidine increases effects of chlorthalidone by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cinnarizine",
            "description": {
                "common": "brimonidine increases effects of cinnarizine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clemastine",
            "description": {
                "common": "brimonidine increases effects of clemastine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clevidipine",
            "description": {
                "common": "brimonidine increases effects of clevidipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clomipramine",
            "description": {
                "common": "clomipramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clonazepam",
            "description": {
                "common": "brimonidine increases effects of clonazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clonidine",
            "description": {
                "common": "brimonidine increases effects of clonidine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clorazepate",
            "description": {
                "common": "brimonidine increases effects of clorazepate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clozapine",
            "description": {
                "common": "brimonidine increases effects of clozapine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "codeine",
            "description": {
                "common": "brimonidine increases effects of codeine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclizine",
            "description": {
                "common": "brimonidine increases effects of cyclizine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclopenthiazide",
            "description": {
                "common": "brimonidine increases effects of cyclopenthiazide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyproheptadine",
            "description": {
                "common": "brimonidine increases effects of cyproheptadine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "desipramine",
            "description": {
                "common": "desipramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexchlorpheniramine",
            "description": {
                "common": "brimonidine increases effects of dexchlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexmedetomidine",
            "description": {
                "common": "brimonidine increases effects of dexmedetomidine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dextromoramide",
            "description": {
                "common": "brimonidine increases effects of dextromoramide by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diamorphine",
            "description": {
                "common": "brimonidine increases effects of diamorphine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diazepam",
            "description": {
                "common": "brimonidine increases effects of diazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "difenoxin hcl",
            "description": {
                "common": "brimonidine increases effects of difenoxin hcl by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diltiazem",
            "description": {
                "common": "brimonidine increases effects of diltiazem by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dimenhydrinate",
            "description": {
                "common": "brimonidine increases effects of dimenhydrinate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diphenhydramine",
            "description": {
                "common": "brimonidine increases effects of diphenhydramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diphenoxylate hcl",
            "description": {
                "common": "brimonidine increases effects of diphenoxylate hcl by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dipipanone",
            "description": {
                "common": "brimonidine increases effects of dipipanone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "doxazosin",
            "description": {
                "common": "brimonidine increases effects of doxazosin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "doxepin",
            "description": {
                "common": "doxepin decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "doxylamine",
            "description": {
                "common": "brimonidine increases effects of doxylamine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "droperidol",
            "description": {
                "common": "brimonidine increases effects of droperidol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "drospirenone",
            "description": {
                "common": "brimonidine increases effects of drospirenone by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "enalapril",
            "description": {
                "common": "brimonidine increases effects of enalapril by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eplerenone",
            "description": {
                "common": "brimonidine increases effects of eplerenone by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "epoprostenol",
            "description": {
                "common": "brimonidine increases effects of epoprostenol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "esmolol",
            "description": {
                "common": "brimonidine increases effects of esmolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "estazolam",
            "description": {
                "common": "brimonidine increases effects of estazolam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethacrynic acid",
            "description": {
                "common": "brimonidine increases effects of ethacrynic acid by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethanol",
            "description": {
                "common": "brimonidine increases effects of ethanol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "etomidate",
            "description": {
                "common": "brimonidine increases effects of etomidate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "felodipine",
            "description": {
                "common": "brimonidine increases effects of felodipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fenoldopam",
            "description": {
                "common": "brimonidine increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "brimonidine increases effects of fluphenazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "flurazepam",
            "description": {
                "common": "brimonidine increases effects of flurazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fosinopril",
            "description": {
                "common": "brimonidine increases effects of fosinopril by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "brinzolamide, fosphenytoin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "furosemide",
            "description": {
                "common": "brimonidine increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "guanfacine",
            "description": {
                "common": "brimonidine increases effects of guanfacine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "haloperidol",
            "description": {
                "common": "brimonidine increases effects of haloperidol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydralazine",
            "description": {
                "common": "brimonidine increases effects of hydralazine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "brimonidine increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydromorphone",
            "description": {
                "common": "brimonidine increases effects of hydromorphone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydroxyzine",
            "description": {
                "common": "brimonidine increases effects of hydroxyzine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "iloperidone",
            "description": {
                "common": "brimonidine increases effects of iloperidone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "iloprost",
            "description": {
                "common": "brimonidine increases effects of iloprost by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "imidapril",
            "description": {
                "common": "brimonidine increases effects of imidapril by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "imipramine",
            "description": {
                "common": "imipramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "indapamide",
            "description": {
                "common": "brimonidine increases effects of indapamide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isradipine",
            "description": {
                "common": "brimonidine increases effects of isradipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ketanserin",
            "description": {
                "common": "brimonidine increases effects of ketanserin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "labetalol",
            "description": {
                "common": "brimonidine increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levorphanol",
            "description": {
                "common": "brimonidine increases effects of levorphanol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lisinopril",
            "description": {
                "common": "brimonidine increases effects of lisinopril by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lofepramine",
            "description": {
                "common": "lofepramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "loprazolam",
            "description": {
                "common": "brimonidine increases effects of loprazolam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lorazepam",
            "description": {
                "common": "brimonidine increases effects of lorazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lormetazepam",
            "description": {
                "common": "brimonidine increases effects of lormetazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "loxapine",
            "description": {
                "common": "brimonidine increases effects of loxapine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "loxapine inhaled",
            "description": {
                "common": "brimonidine increases effects of loxapine inhaled by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "maprotiline",
            "description": {
                "common": "maprotiline decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mecamylamine",
            "description": {
                "common": "brimonidine increases effects of mecamylamine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "meperidine",
            "description": {
                "common": "brimonidine increases effects of meperidine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "meprobamate",
            "description": {
                "common": "brimonidine increases effects of meprobamate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methadone",
            "description": {
                "common": "brimonidine increases effects of methadone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methyclothiazide",
            "description": {
                "common": "brimonidine increases effects of methyclothiazide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metolazone",
            "description": {
                "common": "brimonidine increases effects of metolazone by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metoprolol",
            "description": {
                "common": "brimonidine increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metyrosine",
            "description": {
                "common": "brimonidine increases effects of metyrosine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "midazolam",
            "description": {
                "common": "brimonidine increases effects of midazolam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "minoxidil",
            "description": {
                "common": "brimonidine increases effects of minoxidil by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "moexipril",
            "description": {
                "common": "brimonidine increases effects of moexipril by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "morphine",
            "description": {
                "common": "brimonidine increases effects of morphine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "moxisylyte",
            "description": {
                "common": "brimonidine increases effects of moxisylyte by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "moxonidine",
            "description": {
                "common": "brimonidine increases effects of moxonidine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nadolol",
            "description": {
                "common": "brimonidine increases effects of nadolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nalbuphine",
            "description": {
                "common": "brimonidine increases effects of nalbuphine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nebivolol",
            "description": {
                "common": "brimonidine increases effects of nebivolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nicardipine",
            "description": {
                "common": "brimonidine increases effects of nicardipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nifedipine",
            "description": {
                "common": "brimonidine increases effects of nifedipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nisoldipine",
            "description": {
                "common": "brimonidine increases effects of nisoldipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "nortriptyline decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "olanzapine",
            "description": {
                "common": "brimonidine increases effects of olanzapine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "opium tincture",
            "description": {
                "common": "brimonidine increases effects of opium tincture by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxazepam",
            "description": {
                "common": "brimonidine increases effects of oxazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxycodone",
            "description": {
                "common": "brimonidine increases effects of oxycodone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxymorphone",
            "description": {
                "common": "brimonidine increases effects of oxymorphone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "paliperidone",
            "description": {
                "common": "brimonidine increases effects of paliperidone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "papaveretum",
            "description": {
                "common": "brimonidine increases effects of papaveretum by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "penbutolol",
            "description": {
                "common": "brimonidine increases effects of penbutolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pentazocine",
            "description": {
                "common": "brimonidine increases effects of pentazocine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "brinzolamide, pentobarbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "perindopril",
            "description": {
                "common": "brimonidine increases effects of perindopril by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "brinzolamide, phenobarbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "perphenazine",
            "description": {
                "common": "brimonidine increases effects of perphenazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "brimonidine increases effects of phenobarbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenoxybenzamine",
            "description": {
                "common": "brimonidine increases effects of phenoxybenzamine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phentolamine",
            "description": {
                "common": "brimonidine increases effects of phentolamine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenytoin",
            "description": {
                "common": "brinzolamide, phenytoin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pimozide",
            "description": {
                "common": "brimonidine increases effects of pimozide by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pindolol",
            "description": {
                "common": "brimonidine increases effects of pindolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prazosin",
            "description": {
                "common": "brimonidine increases effects of prazosin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "primidone",
            "description": {
                "common": "brinzolamide, primidone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prochlorperazine",
            "description": {
                "common": "brimonidine increases effects of prochlorperazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "secobarbital",
            "description": {
                "common": "brinzolamide, secobarbital. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of anticonvulsant induced osteomalacia."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Somnolence in children",
            "percent": "50-83"
        },
        {
            "name": "Xerostomia",
            "percent": "10-30"
        },
        {
            "name": "Ocular hyperemia",
            "percent": "10-30"
        },
        {
            "name": "Burning and stinging",
            "percent": "10-30"
        },
        {
            "name": "Headache",
            "percent": "10-30"
        },
        {
            "name": "Blurring",
            "percent": "10-30"
        },
        {
            "name": "Foreign body sensation",
            "percent": "10-30"
        },
        {
            "name": "Fatigue",
            "percent": "10-30"
        },
        {
            "name": "drowsiness",
            "percent": "10-30"
        },
        {
            "name": "Conjunctival follicles",
            "percent": "10-30"
        },
        {
            "name": "Ocular allergic reactions",
            "percent": "10-30"
        },
        {
            "name": "Ocular pruritus",
            "percent": "5-10"
        },
        {
            "name": "Blurred vision",
            "percent": "5-10"
        },
        {
            "name": "Dysgeusia",
            "percent": "1-5"
        },
        {
            "name": "Blepharitis",
            "percent": "1-5"
        },
        {
            "name": "Dermatitis",
            "percent": "1-5"
        },
        {
            "name": "Dry eye",
            "percent": "1-5"
        },
        {
            "name": "Foreign body sensation",
            "percent": "1-5"
        },
        {
            "name": "Headache",
            "percent": "1-5"
        },
        {
            "name": "Hyperemia",
            "percent": "1-5"
        },
        {
            "name": "Ocular discharge",
            "percent": "1-5"
        },
        {
            "name": "Ocular discomfort",
            "percent": "1-5"
        },
        {
            "name": "Ocular keratitis",
            "percent": "1-5"
        },
        {
            "name": "Ocular pain",
            "percent": "1-5"
        },
        {
            "name": "Ocular pruritus",
            "percent": "1-5"
        },
        {
            "name": "Rhinitis",
            "percent": "3-9"
        },
        {
            "name": "Corneal staining",
            "percent": "3-9"
        },
        {
            "name": "erosion",
            "percent": "3-9"
        },
        {
            "name": "Photophobia",
            "percent": "3-9"
        },
        {
            "name": "Eyelid erythema",
            "percent": "3-9"
        },
        {
            "name": "Ocular ache",
            "percent": "3-9"
        },
        {
            "name": "pain",
            "percent": "3-9"
        },
        {
            "name": "Ocular dryness",
            "percent": "3-9"
        },
        {
            "name": "Tearing",
            "percent": "3-9"
        },
        {
            "name": "Upper respiratory symptoms",
            "percent": "3-9"
        },
        {
            "name": "Eyelid edema",
            "percent": "3-9"
        },
        {
            "name": "Conjunctival edema",
            "percent": "3-9"
        },
        {
            "name": "Dizziness",
            "percent": "3-9"
        },
        {
            "name": "Blepharitis",
            "percent": "3-9"
        },
        {
            "name": "Ocular",
            "percent": "3-9"
        },
        {
            "name": "Irritation",
            "percent": "3-9"
        },
        {
            "name": "Gastrointestinal symptoms",
            "percent": "3-9"
        },
        {
            "name": "Asthenia",
            "percent": "3-9"
        },
        {
            "name": "Conjunctival blanching",
            "percent": "3"
        },
        {
            "name": "Abnormal vision",
            "percent": "3"
        },
        {
            "name": "Muscular pain",
            "percent": "3"
        },
        {
            "name": "Lid crusting",
            "percent": "3"
        },
        {
            "name": "Conjunctival hemorrhage",
            "percent": "3"
        },
        {
            "name": "Abnormal taste",
            "percent": "3"
        },
        {
            "name": "Insomnia",
            "percent": "3"
        },
        {
            "name": "Conjunctival discharge",
            "percent": "3"
        },
        {
            "name": "Depression",
            "percent": "3"
        },
        {
            "name": "Hypertension",
            "percent": "3"
        },
        {
            "name": "Anxiety",
            "percent": "3"
        },
        {
            "name": "Palpitations",
            "percent": null
        },
        {
            "name": "arrhythmias",
            "percent": null
        },
        {
            "name": "Nasal dryness",
            "percent": null
        },
        {
            "name": "Syncope",
            "percent": null
        },
        {
            "name": "Allergic reactions",
            "percent": null
        },
        {
            "name": "Alopecia",
            "percent": null
        },
        {
            "name": "Chest pain",
            "percent": null
        },
        {
            "name": "Conjunctivitis",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Diplopia",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Dry mouth",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Dyspepsia",
            "percent": null
        },
        {
            "name": "Eye fatigue",
            "percent": null
        },
        {
            "name": "Hypertonia",
            "percent": null
        },
        {
            "name": "Keratoconjunctivitis",
            "percent": null
        },
        {
            "name": "Keratopathy",
            "percent": null
        },
        {
            "name": "Kidney pain",
            "percent": null
        },
        {
            "name": "Lid margin crusting or sticky sensation",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Pharyngitis",
            "percent": null
        },
        {
            "name": "Tearing",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        }
    ]
}